On Demand 2021 Friday General Sessions

This collection covers general sessions from Friday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Non-Infectious Complications of Immunodeficiency
  • Physician Health and Wellness in Allergy and Immunology: Challenges and Strategies
  • Owning Anaphylaxis- An Update on Anaphylaxis
  • Regional Dermatitis: How to Make Heads or Tails out of Rashes
  • Allergy and Immunology Issues During Travel
  • The Multidisciplinary Approach to the Management of Chronic Cough
  • Solving The Puzzle of Food Allergy Prevention
  • Supplements and More: Achieving A Global Approach to the Patient Who Wants More than just Traditional Therapies

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 11.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Identify various types of non-infectious complications seen in patients with immunodeficiency disorders
  • Demonstrate knowledge of dysregulated immune pathways which contribute to non-infectious complications of immunodeficiency disorders
  • Evaluate the impact of new immune therapies on management of patients with immunodeficiency disorders
  • Formulate and categorize strategies to improve practice wellness and efficiency
  • Demonstrate the ability to summarize wellness data involving allergy and immunology physicians
  • Compare and contrast potential solutions to improve individual physician resilience
  • Discuss the definition of Anaphylaxis based on the newest practice parameter
  • Describe both mechanisms involved in Anaphylaxis and Anaphylaxis-like reactions
  • Understand the evidence of epinephrine as first line therapy for anaphylaxis and ways to manage epinephrine hesitancy
  • Discuss the various diseases (contact dermatitis, atopic dermatitis, psoriasis, etc.) that affect specific body areas
  • Verbalize the tools/methods to distinguish between diagnoses of that specific area
  • Identify the management of the regional dermatitis
  • Advise their immunodeficiency patients on precautions they should take during travel
  • Counsel their food allergic and asthma patients on good travel habits
  • Have a better approach to presenting the benefits of vaccines to parents ambivalent about vaccinating their children
  • Describe the mechanisms underlying chronic cough
  • Develop a comprehensive diagnostic and therapeutic approach to chronic cough with updates in medical management
  • Discuss the role of speech language pathology in the management of chronic cough
  • Discuss the role of the skin and emollient application in preventing food allergy
  • Describe the role of food diversity and the microbiome in food allergy prevention
  • Highlight innovative approaches in preventing food allergy
  • Recognize the frequent practice of integrative (complementary and alternative) medicine
  • Describe the potential risks and benefits associated with integrative medicine
  • Provide a critical review of the literature supporting and opposing the use of integrative medicine to treat atopic disorders
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 11.75 AMA PRA Category 1 Credit™
  • 11.75 Attendance
Course opens: 
11/19/2021
Course expires: 
11/18/2024
Part of: 
On Demand ACAAI 2021 Annual Scientific Meeting General Sessions
Rating: 
0

Marcella R. Aquino, MD, FACAAI

Donald V. Belsito, MD

J. Andrew Bird, MD, FACAAI

Helen Brough, MA, MSc, PhD, MBBS, FAAAAI, FRCPCH

Christina E. Ciaccio, MD, MSc, FACAAI

Mary Beth Fasano, MD, MSPH, FACAAI

Lisa R. Forbes-Satter, MD

Joseph P. Forester, DO, FACAAI

Joseph F. Fowler, Jr., MD 

Alan B. Goldsobel, MD, FACAAI 

Payel Gupta, MD, FACAAI 

Ruchi Gupta, MD, PhD

Joseph K. Han, MD

Angela D. Hogan, MD, FACAAI

Randy J. Horwitz, MD, PhD

Richard S. Irwin, MD

Jennifer Koplin, MD, PhD

Monica G. Lawrence, MD

Stephanie Logsdon, MD, FACAAI

Jay A. Lieberman, MD, FACAAI

Gailen D. Marshall, Jr., MD, PhD, FACAAI

Stephanie L. Mawhirt, DO

Anil Nanda, MD, FACAAI

Mervat Nassef, MD, FACAAI

Anna Nowak-Wegrzyn, MD, FACAAI

Maeve O'Connor, MD, FACAAI

Jessica B. Perkins, MD

Benjamin Prince, MD

Lawrence A. Schwartz, DO, FACAAI

Monica Shaffer, MA, CCC-SLP

Mandel R. Sher, MD, FACAAI

Gary K. Soffer, MD

Puneet Shroff, MD, FACAAI 

J. Wesley Sublett, MD, MPH, FACAAI

Carina Venter, PhD, RD

James Verbsky, MD, PhD

Julie Wang, MD, FACAAI

Jeff Yu, MD

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 11.75 AMA PRA Category 1 Credit™
  • 11.75 Attendance
Please login or create an account to take this course.